title: Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
abstract: OBJECTIVE
  This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel.
  
  
  METHODS
  Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital.
  
  
  RESULTS
  Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7-8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11-16). At multivariate analysis, a higher Gleason score (≥ 8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18-0.72); however, the higher Gleason score showed no statistical impact on overall survival.
  
  
  CONCLUSIONS
  We hypothesize that the Gleason score has the potential to be incorporated in the clinical decision-making process for definition of treatment strategy in docetaxel-pretreated castration-resistant prostate cancer patients. We encourage further experimentation in this setting.
authors.affiliation: Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology & Oncology, University Federico II, Napoli, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Buonerba
authors.forename: Gregory R
authors.initials: GR
authors.lastname: Pond
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Piera
authors.initials: P
authors.lastname: Federico
authors.forename: Pasquale
authors.initials: P
authors.lastname: Rescigno
authors.forename: Livio
authors.initials: L
authors.lastname: Puglia
authors.forename: Davide
authors.initials: D
authors.lastname: Bosso
authors.forename: Antonella
authors.initials: A
authors.lastname: Virtuoso
authors.forename: Tania
authors.initials: T
authors.lastname: Policastro
authors.forename: Michela
authors.initials: M
authors.lastname: Izzo
authors.forename: Luca
authors.initials: L
authors.lastname: Vaccaro
authors.forename: Matteo
authors.initials: M
authors.lastname: Ferro
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
authors.forename: Sisto
authors.initials: S
authors.lastname: Perdonà
authors.forename: Giovannella
authors.initials: G
authors.lastname: Palmieri
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
mesh_terms: D000368:Aged; D002369:Castration; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D043823:Taxoids; C552428:cabazitaxel; D017430:Prostate-Specific Antigen